News

Morningstar7d
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
It is highly similar to the reference product Eylea® (aflibercept ... with or without occlusion may occur following intravitreal injections. Patients and/or caregivers should be instructed ...
Le Lézard7d
Biocon Biologics Secures Market Entry Date for Yesafilitm, an Interchangeable Biosimilar to Eylea®, in the U.S.
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with ...
Biocon Biologics Ltd.: Biocon Biologics Secures Market Entry Date for Yesafili, an Interchangeable Biosimilar to Eylea, in the U.S.
BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...
Kalaris Therapeutics initiated with an Outperform at William Blair
William Blair initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $21 fair value estimate. Kalaris is a ...
Hosted on MSN20d
Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge
Similar to Vabysmo, it is also available in both vials and prefilled syringes, and administered via intravitreal injection. Eylea, along with a higher-dose version at 8mg, generated global sales ...
Medscape20d
Sponsor Pulls Plug on Trials of Add-On AMD Treatment
One trial evaluated sozinibercept in combination with aflibercept 2 mg (Eylea), the other in combination ... The aflibercept trial, known as COAST, evaluated intravitreal sozinibercept every ...
pharmaphorum8d
Oxurion files for bankruptcy as DME drug fails
The KALAHARI study compared intravitreal injections of THR-149 to Regeneron and Bayer’s anti-VEGF antibody Eylea (aflibercept), a widely-used therapy for DME, in 112 patients for whom the ...